CRDL

Cardiol Therapeutics Inc.

2.20 USD

Last updated Sep 4, 19:59 UTC

Yesterday HIGH

$2.2

Yesterday LOW

$2.08

52w HIGH

$2.28

52w LOW

$0.88

EPS

-0.04

PE

-60.97

Next Earnings

Nov 12, 2026

Overview News Government Trades Fundamentals

Cardiol Therapeutics Inc. stock is up 63.81% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Insights

Wed Aug 26, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session

Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock increased by 15.7%
Benzinga Newsdesk

Mon Aug 17, 2026

Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $10

Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $8 to $10.
Benzinga Newsdesk

Tue Jul 14, 2026

HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
Benzinga Newsdesk

Tue Jul 14, 2026

Cardiol Therapeutics Announces Publication Of Phase II MAvERIC Study Results In The Journal of the American Heart Association

The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment. The publication describes clinical findings in which CardiolRx™ was associated with rapid and sustained reductions in
Benzinga Insights

Wed Jun 3, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Newsdesk

Wed Apr 1, 2026

Cardiol Advances Key Studies and Secures Funding to Push New Heart Treatments Forward

Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease,